Drug treatment of stable angina pectoris in the elderly: Defining the place of calcium channel antagonists

Drugs and Aging

Volumn 20, Issue 11, 2003, Pages 805-815

  Kumar, Sanjay ^a   Hall, Roger J C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FELODIPINE; GALLOPAMIL; ISRADIPINE; METOPROLOL; NICARDIPINE; NICORANDIL; NIFEDIPINE; NITRATE; VERAPAMIL;

AGED; BINDING AFFINITY; BRADYCARDIA; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PREFERENCE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE PERFUSION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE;

AGED; ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; META-ANALYSIS; MYOCARDIAL INFARCTION;

EID: 0141426795     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320110-00002     Document Type: Review

References (91)

1. Wenger NK, O'Rourke RA, Marcus FI. The care of elderly patients with cardiovascular disease. Ann Intern Med 1988; 109 (5): 425-8
2. Simons LA. Epidemiologic considerations in cardiovascular diseases in the elderly: international comparisons and trends. Am J Cardiol 1989; 63 (16): 5H-8H
3. Fleg JL, Gerstenblith G, Zonderman AB, et al. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia detected by thallium scintigraphy and electrocardiography in asymptomatic volunteers. Circulation 1990; 81 (2): 428-36
4. Rihal CS, Gersh BJ, Yusuf S. Chronic coronary artery disease: coronary artery bypass surgery versus percutaneous transluminal coronary angioplasty versus medical. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors. Evidence based cardiology. London: BMJ Books, 1999: 368-92
5. Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension: a reappraisal. Drugs 1998; 55 (4): 509-17
6. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 5 (4): 206-8
7. Leenen FH. Clinical relevance of 24h blood pressure control by 1,4-dihydropyridines. Am J Hypertens 1996; 9 (10 Pt 2): 97S-104S
8. Purcell H, Waller DG, Fox K. Calcium antagonists in cardiovascular disease. Br J Clin Pract 1989; 43 (10): 369-79
9. Wenzel RR, Allegranza G, Binggeli C, et al. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol 1997; 29 (7): 1607-14
10. Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. Eur Heart J 1996; 17 (8): 1142-7
11. Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure: UK Study Group. Br Heart J 1995; 73 (5): 428-33
12. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996; 15 (2): 91-106
13. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335 (15): 1107-14
14. Schwartz A. Molecular and cellular aspects of calcium channel antagonism. Am J Cardiol 1992; 70 (16): 6F-8F
15. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1977; 17: 149-66
16. Kojda G, Klaus W, Werner G, et al. Reduced responses of nitrendipine in PGF2 alpha-precontracted porcine isolated arteries after pretreatment with methylene blue. Basic Res Cardiol 1990; 85 (5): 461-6
17. Gunther J, Dhein S, Rosen R, et al. Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries. Basic Res Cardiol 1992; 87 (5): 452-60
18. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97 (6): 576-80
19. Tanguay M, Jasmin G, Blaise G, et al. Coronary and cardiac sensitivity to the vasoselective benzothiazepine-like calcium antagonist, clentiazem, in experimental heart failure. Cardiovasc Drugs Ther 1997; 11 (1): 71-9
20. Dhein S, Salameh A, Berkels R, et al. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs 1999; 58 (3): 397-404
21. John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens 2000; 18 (4): 363-74
22. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22 (1): 36-52
23. Puddu P, Puddu GM, Zaca F, et al. Endothelial dysfunction in hypertension. Acta Cardiol 2000; 55 (4): 221-32
24. Barua RS, Ambrose JA, Eales-Reynolds LJ, et al. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 2001; 104 (16): 1905-10
25. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335 (8698): 1109-13
26. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82 (6): 1940-53
27. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996; 276 (10): 785-91
28. Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2000; 35 (3): 592-9
29. Tison P, Ulicna L, Jakubovska Z, et al. Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension. Am J Hypertens 1994; 7 (7 Pt 2): 46S-9S
30. Berkels R, Klaus W, Boller M, et al. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process. Thromb Haemost 1994; 72 (2): 309-12
31. Rinaldi CA, Linka AZ, Masani ND, et al. Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning. Circulation 1998; 98 (8): 749-56
32. Ardissino D, Savonitto S, Egstrup K, et al. Selection of medical treatment in stable angina pectoris: results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1995; 25 (7): 1516-21
33. Crake T, Mulcahy D, Wright C, et al. Labetalol in the treatment of stable exertional angina pectoris: a comparison with nifedipine. Eur Heart J 1988; 9 (11): 1200-5
34. Di Somma S, de Divitiis M, Bertocchi F, et al. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine. Cardiologia 1996; 41 (7): 635-43
35. Findlay IN, MacLeod K, Ford M, et al. Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function. Br Heart J 1986; 55 (3): 240-5
36. Kawanishi DT, Reid CL, Morrison EC, et al. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol 1992; 19 (2): 409-17
37. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris: results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996; 27 (2): 311-6
38. Wallace WA, Wellington KL, Chess MA, et al. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am J Cardiol 1994; 73 (1): 23-8
39. Frishman WH, Klein NA, Strom JA, et al. Superiority of verapamil to propranolol in stable angina pectoris: a double-blind, randomized crossover trail. Circulation 1982; 65 (1 Pt 2): 151-9
40. Hauf-Zachariou U, Blackwood RA, Gunawardena KA, et al. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur J Clin Pharmacol 1997; 52 (2): 95-100
41. Deanfield JE, Detry JM, Lichtlen PR. et al. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24 (6): 1460-7
42. Humen DP, Kostuk WJ. Clinical response and effects on left ventricular function of isosorbide dinitrate added to propranolol or diltiazem monotherapy in patients with chronic stable angina. Can J Cardiol 1991; 7 (2): 74-80
43. van Dijk RB, Lie KI, Crijns HJ. Diltiazem in comparison with metoprolol in stable angina pectoris. Eur Heart J 1988; 9 (11): 1194-9
44. Frishman WH, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999; 83 (4): 507-14
45. Santoro G, Savonitto S, Di Bello V, et al. Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris. Am J Cardiol 1991; 68 (5): 457-62
46. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol 1995; 25 (3): 619-25
47. Zucker DR, Griffith JL, Beshansky JR, et al. Presentations of acute myocardial infarction in men and women. J Gen Intern Med 1997; 12 (2): 79-87
48. Just H, Frey M, Zehender M. Calcium antagonist drugs in hypertensive patients with angina pectoris. Eur Heart J 1996; 17 Suppl. G: 20-4
49. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92 (5): 1326-31
50. Alderman MH, Cohen H, Roque R, et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349 (9052): 594-8
51. Abascal VM, Larson MG, Evans JC, et al. Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart Study. Arch Intern Med 1998; 158 (17): 1882-6
52. Stone PH, Muller JE, Turi ZG, et al. Efficacy of nifedipine therapy in patients with refractory angina pectoris: significance of the presence of coronary vasospasm. Am Heart J 1983; 106 (4 Pt 1): 644-52
53. Egstrup K, Andersen Jr PE. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol 1993; 71 (2): 177-83
54. Scheidt S, LeWinter MM. Hermanovich J, et al. Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial. Am J Cardiol 1986; 58 (9): 715-21
55. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274 (8): 620-5
56. Pahor M, Guralnik JM, Corti MC, et al. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43 (11): 1191-7
57. Jollis JG, Simpson Jr RJ, Chowdhury MK, et al. Calcium channel blockers and mortality in elderly patients with myocardial infarction. Arch Intern Med 1999; 159 (19): 2341-8
58. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Dihiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee: and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83 (1): 52-60
59. Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996; 94 (3): 346-52
60. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27 (5): 335-71
61. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990; 66 (10): 779-85
62. Rehnqvist N, Hjemdahl P, Billing E. et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris: The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17 (1): 76-81
63. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol 1996; 77 (5): 365-9
64. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356 (9246): 1949-54
65. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353 (9169): 2001-07
66. Opie LH. First line drugs in chronic stable effort angina: the case for newer, longer-acting calcium channel blocking agents. J Am Coll Cardiol 2000; 36 (6): 1967-71
67. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III: Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96 (3): 856-63
68. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281 (20): 1927-36
69. Buckley MM, Grant SM, Goa KL, et al: Diltiazem: a reappraisal of its pharmacological properties and therapeutic use. Drugs 1990; 39 (5): 757-806
70. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev 1993; 73 (2): 413-67
71. Luomanmaki K, Inkovaara J, Hartikainen M, et al. Efficacy and tolerability of isradipine and metoprolol in treatment of hypertension: the Finnish Isradipine Study in Hypertension (FISH). J Cardiovasc Pharmacol 1992; 20 (2): 296-303
72. Philipp T, Anlauf M, Distler A, et al. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ 1997 Jul 19; 315 (7101): 154-9
73. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33 (7): 2092-197
74. Brogden RN, McTavish D. Nifedipine gastrointestinal therapeutic system (GITS): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs 1995; 50 (3): 495-512
75. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999; 340 (8): 618-26
76. Abrams J. Nitrate tolerance and dependence. Am Heart J 1980; 99 (1): 113-23
77. Rajaratnam R, Brieger DB, Hawkins R, et al. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol 1999; 83 (7): 1120-4, A9
78. IONA Study Group. Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management. Heart 2001; 85 (6): E9
79. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339 (8): 489-97
80. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277 (2): 115-21
81. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9-13
82. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996; 94 (11): 2800-6
83. Hansen JF, Hagerup L, Sigurd B, et al. Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. Am Heart J 1997; 134 (2 Pt 2): S48-52
84. Elkayam U, Shotan A, Mehra A, et al. Calcium channel blockers in heart failure. J Am Coll Cardiol 1993; 22 (4 Suppl. A): 139A-44A
85. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322 (22): 1561-6
86. Terpstra WF, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19 (2): 303-9
87. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104 (11): 1248-54
88. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757-64
89. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340 (9): 677-84
90. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356 (9227): 359-65
91. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999 Nov 20; 354 (9192): 1751-6